The improved cash position and reduced burn support near-term execution of the Phase 2 trial. Investors should monitor Q2 2026 for FDA IND feedback and Q4 2026 for full Phase 1b extension results, which could serve as a catalyst if they confirm disease-modifying effects.
Price Chart
Executive Summary
Gain Therapeutics reported financial results for 2025, showing a slight reduction in net loss to $20.2M from $20.4M in 2024, driven by lower R&D and G&A expenses. The company highlighted clinical progress with its lead candidate GT-02287 in Parkinson’s disease, including stable MDS-UPDRS scores and an 81% reduction in CSF GluSph levels, with Phase 1b extension data expected in 2026. Cash increased to $20.8M, supporting planned Phase 2 initiation in Q3 2026.
Key Financial Metrics
Key Facts
- Net loss decreased to $20.16M in 2025 from $20.41M in 2024, with EPS improving to -$0.61 from -$0.89.
- R&D expenses declined by $0.6M to $10.2M, and G&A dropped by $1.1M to $8.5M, primarily due to lower stock-based compensation and legal fees.
- Cash, cash equivalents, and marketable securities nearly doubled to $20.8M from $10.4M in 2024.
- Phase 1b data for GT-02287 showed stable MDS-UPDRS scores and 81% reduction in CSF glucosylsphingosine (GluSph) in elevated-baseline patients after 90 days.
- IND clearance for Phase 2 trial of GT-02287 expected in Q2 2026, with trial initiation anticipated in Q3 2026.
Financial Impact
Net loss reduced by $250K year-over-year; operating expenses down $1.64M. Cash position increased by $10.4M, providing runway into 2027.
Risk Factors
- No revenue-generating products; company remains pre-revenue and dependent on capital markets.
- Clinical development risk: GT-02287 is still early-stage, and Phase 2 may not replicate Phase 1b signals.
- Foreign exchange exposure due to Swiss franc-denominated costs impacting expense volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262864 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.15 (−33.14%) |
Oct 1, 2026 26d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.15 (−33.14%) |
Aug 11, 2026 11w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.15 (−44.17%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.15 (−30.72%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.15 (−43.35%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.15 (−43.35%) |
May 26, 2026 22w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.15 (−36.81%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.15 (−36.81%) |
Apr 28, 2026 26w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.15 (−34.66%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.15 (−39.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers